Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies.
The incidence of adenocarcinoma of the esophagogastric junction (AEG) is dramatically increasing in Western countries, while it is not increasing in Eastern countries. Siewert type I tumors are observed less frequently in Eastern countries in comparison to Western countries. On the other hand, other clinicopathological features of AEG, including age, male-to-female ratio, pathological grade, tumor progression, and prognosis, are similar in Western and Eastern countries. Two surgical phase III trials have indicated that AEG type I should be treated surgically as esophageal cancer, while types II and III should be regarded as true gastric cancer. No phase III trials have demonstrated a significant interaction comparing hazard ratios for death between AEG and true gastric cancer in the subset analyses with regard to chemotherapy.
Hasegawa
Shinichi
S
Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, 241-0815, Japan.
Yoshikawa
Takaki
T
D000230:Adenocarcinoma / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D017326:Clinical Trials, Phase III as Topic; D004938:Esophageal Neoplasms / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D004943:Esophagogastric Junction / Q000473:pathology; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D011379:Prognosis; D013274:Stomach Neoplasms / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*